Attending Physician, Oncology, Cleveland Clinic
Oncology
Dr. Hetty E. Carraway, MD
|
|
Give Review
Hetty E. Carraway is an expert in the field of Oncology. She graduated from University of Massachusetts Medical School. University of Massachusetts Medical School is ranked 49/12 in Research/PrimaryCare. Hetty Carraway has written publications. She has 24 publications published with PubMed. The lastest paper is: 'Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes.' She accepts Medicare.
Publications
- Genomic patterns associated with hypoplastic compared to hyperplastic Myelodysplastic syndromes.
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in Myeloid neoplasms.
- The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
- HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation.
- Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/Leukemia.
- Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory Acute leukaemias.
- Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed Acute myelogenous leukemia.
- Epigenetic differences in cytogenetically normal versus abnormal Acute myeloid leukemia.
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for Acute leukemias.
- DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay.
- Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
- Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk Acute myelogenous leukemia.
- Enzymatic incorporation of multiple dyes for increased sensitivity in QD-FRET sensing for DNA methylation detection.
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with Myeloid malignancies.
- Promoter hypermethylation in sentinel lymph nodes as a marker for breast Cancer recurrence.
- Monitoring methylation and gene expression in Cancer.
- Tamoxifen-stimulated growth of breast Cancer due to p21 loss.
- A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliom...
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory Acute leukemias.
- DNA demethylating agents and histone deacetylase inhibitors in hematologic Malignancies.
- LKB1 protein expression in human breast Cancer.
- Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast Cancer.
- Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast Cancer.
Schools
University Of Massachusetts Medical School
Johns Hopkins
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Johns Hopkins Carey Business School -
Johns Hopkins University -
University of Massachusetts Medical School
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1457319717 | |
| NPPES Provider LastName | CARRAWAY | |
| NPPES Provider FirstName | HETTY | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 41.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457319717 |
| Last Name Of The Provider | CARRAWAY |
| First Name Of The Provider | HETTY |
| View All |
Similar Doctors
|
|
Dr. Matthew J. Frigault, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yvette L. Kasamon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mian K. Khalid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stuart A. Grossman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Kanakry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ephraim J. Fuchs, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael J. Purtell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James G. Herman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Humphrey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathan C. Nussbaum, MD |